DOCSLIB.ORG

JPET #84467 1 Title Page Effects of the NMDA Receptor Antagonist

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
JPET #84467 1 Title Page Effects of the NMDA Receptor Antagonist JPET Fast Forward. Published on March 11, 2005 as DOI: 10.1124/jpet.105.084467 JPET FastThis article Forward. has not beenPublished copyedited on and Marchformatted. 11, The 2005 final version as DOI:10.1124/jpet.105.084467 may differ from this version. JPET #84467 Title Page Effects of the NMDA receptor antagonist perzinfotel (EAA-090) on chemically-induced thermal hypersensitivity Downloaded from Michael R. Brandt, Terri A. Cummons, Lisa Potestio, Stacey J. Sukoff and Sharon Rosenzweig-Lipson jpet.aspetjournals.org Neuroscience Discovery Research, Wyeth Research, Princeton, NJ (MRB, TAC, LP, SJS, SRL) at ASPET Journals on September 30, 2021 1 Copyright 2005 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on March 11, 2005 as DOI: 10.1124/jpet.105.084467 This article has not been copyedited and formatted. The final version may differ from this version. JPET #84467 Running Title: Effects of perzinfotel on thermal hypersensitivity Corresponding Author: Michael R. Brandt, Ph.D. Analgesics Drug Discovery Johnson & Johnson PRDUS Welsh and McKean Roads Spring House, PA 19477-0776 Phone: (215) 628-5434 Downloaded from Fax: (215) 628-3297 E-mail: [email protected] jpet.aspetjournals.org Text pages: 32 Tables: 1 Figures: 8 at ASPET Journals on September 30, 2021 References: 40 (40) Word Count: Abstract: 193 (250) Introduction: 335 (750) Discussion: 1498 (1500) Abbreviations: perzinfotel (EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)- en-2-yl)-ethyl]phosphonic acid, selfotel (CGS-19755; cis-4-(phosphonomethyl) piperidinge-2-carboxylic acid), dizocilpine [(MK-801; (+)-10,11-dihydro-5-methyl-5H- dibenzo [a,d]cyclohepten-5, 10 imine (Z)-2-butenedioate (1:1)]), CGP-39653; D,L-(E)-2- amino-4-propyl-5-phosphono-3-pentenoic acid Section Assignment: Neuropharmacology 2 JPET Fast Forward. Published on March 11, 2005 as DOI: 10.1124/jpet.105.084467 This article has not been copyedited and formatted. The final version may differ from this version. JPET #84467 Abstract Perzinfotel (EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)- ethyl]phosphonic acid) is a selective, competitive NMDA receptor antagonist with high affinity for the glutamate site. The current study evaluated whether perzinfotel would have antinociceptive effects or block thermal hypersensitivity associated with the administration of chemical irritants in rats. Perzinfotel lacked antinociceptive effects but dose- and time-dependently blocked prostaglandin E2 (PGE2)- and capsaicin-induced Downloaded from thermal hypersensitivity in a warm-water tail withdrawal assay in rats. Doses of 10 mg/kg intraperitoneal (IP) or 100 mg/kg oral (PO) blocked PGE2-induced jpet.aspetjournals.org hypersensitivity by 60-80%. The magnitude of reversal was greater than other negative modulators of the NMDA receptor studied, such as un-competitive channel blockers (e.g., memantine, dizocilpine and ketamine), a NR2B selective antagonist (e.g., at ASPET Journals on September 30, 2021 ifenprodil), and other glutamate antagonists (e.g., selfotel, CPP, CGP-39653), up to doses that suppressed operant rates of responding. In contrast to other negative modulators of the NMDA receptor studied, which typically decreased operant rates of responding at doses that lacked antinociceptive effects, perzinfotel did not modify response rates at doses that blocked irritant-induced thermal hypersensitivity. Collectively, these studies demonstrate that perzinfotel has therapeutic ratios for effectiveness versus adverse effects superior to those seen with other competitive and un-competitive NMDA receptor antagonists studied. 3 JPET Fast Forward. Published on March 11, 2005 as DOI: 10.1124/jpet.105.084467 This article has not been copyedited and formatted. The final version may differ from this version. JPET #84467 Introduction Excitatory amino acids (EAAs) acting at NMDA receptors play a role in both acute and chronic pain. Increases in afferent input and glutamate release within the spinal cord have been observed after peripheral injection of an irritant (e.g., carrageenan) or tissue injury (Sluka and Westlund, 1993; Kawamata and Omote, 1996; Dickenson et al., 1997). Repeated stimulation of primary afferent fibers can progressively increase the magnitude and duration of action potentials in spinal cord (often termed ‘windup’), which Downloaded from can lead to central sensitization (Ma and Woolf, 1995). This neuronal hyperexcitability manifests itself in a lowered threshold to evoked activity (i.e., hyperalgesia), an jpet.aspetjournals.org expansion of receptive fields (i.e., secondary hypersensitivity), and an ability of non-noxious input to evoke neuronal activity (i.e., allodynia). In preclinical studies, NMDA receptor antagonists reverse neuronal hyperexcitability and reverse at ASPET Journals on September 30, 2021 hypersensitivity in several inflammatory and neuropathic animal pain models associated with various pathophysiologic mechanisms (Mao et al., 1993; Chaplan et al., 1997; Suzuki et al., 2001). In clinical studies, NMDA receptor antagonists, such as ketamine and dextromethorphan, reduce windup pain, spontaneous pain, hyperalgesia and allodynia in patients with post-herpetic neuralgia pain, phantom limb pain, and diabetic neuropathy pain (Stubhaug and Breivik, 1997; Rabben et al., 1999; Sang, 2000). However, the narrow separation between effectiveness and adverse effects, including sedation and psychotomimetic effects, of clinically available NMDA receptor antagonists has severely hampered their utility for the treatment of neuropathic pain. Perzinfotel is a selective, competitive small molecule antagonist that blocks the actions of glutamate at the NMDA receptor (Kinney et al., 1998; Childers et al., 2002; 4 JPET Fast Forward. Published on March 11, 2005 as DOI: 10.1124/jpet.105.084467 This article has not been copyedited and formatted. The final version may differ from this version. JPET #84467 Sun et al., 2004). Previous studies have demonstrated its effectiveness in several animal stroke models and anticonvulsant models (Childers et al., 2002). Importantly, perzinfotel has an adverse effect profile superior to many other reported competitive (e.g., CGS- 19755) and un-competitive (e.g., dizocilpine) antagonists (Kinney et al., 1998; Childers et al., 2002). Given the apparent involvement of NMDA receptors in pain conditions, perzinfotel was evaluated in preclinical pain assays to determine whether the compound would have antinociceptive, antiallodynic or antihyperalgesic effects. Downloaded from jpet.aspetjournals.org at ASPET Journals on September 30, 2021 5 JPET Fast Forward. Published on March 11, 2005 as DOI: 10.1124/jpet.105.084467 This article has not been copyedited and formatted. The final version may differ from this version. JPET #84467 Materials and Methods Animal maintenance and research were conducted in accordance with the National Research Council’s policies and guidelines for the handling and use of laboratory animals outlined in the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996). The laboratory facility was licensed by the United States Department of Agriculture and accredited by the American Association for Accreditation of Laboratory Animal Care. Research protocols were approved by the Downloaded from Wyeth Institutional Animal Care and Use Committee in accordance with the guidelines of the Committee for Research and Ethical Issues of IASP (Zimmermann, 1983). jpet.aspetjournals.org Subjects. Male Sprague-Dawley rats (Charles River, Kingston/Stoneridge, NY) weighing 200-250g at time of arrival were individually housed in wire cages in a climate- at ASPET Journals on September 30, 2021 controlled room. A 12-hour light/dark cycle (lights on at 06:30) was in effect for all animals and water was available ad libitum. In the operant responding study, rats were food restricted to 10-15 g food post-session and food pellets earned during sessions. For all oral dosing studies, rats were fasted for approximately 16 hr before drug administration. With these exceptions, all other rats were feed ad libitum. Thermal sensitivity assessed by warm-water tail withdrawal. To asses baseline thermal sensitivity, the terminal 10 cm of the tail was placed into water warmed to 34, 38, 42, 46, 50, 54 or 58 °C. The latency in seconds for the animal to remove the tail from the water was used as a measure of nociception. If the animal did not remove the tail within 20 sec, the experimenter removed the tail and a maximum latency of 20 6 JPET Fast Forward. Published on March 11, 2005 as DOI: 10.1124/jpet.105.084467 This article has not been copyedited and formatted. The final version may differ from this version. JPET #84467 sec was recorded. The antinociceptive effects of morphine or perzinfotel were evaluated in a cumulative dosing paradigm. Under this procedure, doses of morphine or perzinfotel, increasing in 0.5 log unit increments, were administered intraperitoneal (IP) every 30 min. Tail-withdrawal latencies were assessed during the 5-min period at the end of each 30 min period (i.e., 25-30 min after drug administration). Downloaded from PGE2- and capsaicin-induced thermal hypersensitivity assessed by warm- water tail withdrawal. Following the assessment of baseline thermal sensitivity, thermal hypersensitivity was produced by a intradermal (ID) 50 µL injection of jpet.aspetjournals.org prostaglandin E2 (PGE2; Sigma, St. Louis, MO) or capsaicin (Sigma, St. Louis, MO) into the distal 1 cm of
Load more

Recommended publications
  • WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 498/04 (2006.01) A61K 31/5365 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 519/00 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IB20 17/050844 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 15 February 2017 (15.02.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/298,657 23 February 2016 (23.02.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, New York, New York 10017 (US).
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest Et A1
    US007964607B2 (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest et a1. (45) Date of Patent: Jun. 21, 2011 (54) PYRAZOLO[3,4-D]PYRIMIDINE FOREIGN PATENT DOCUMENTS COMPOUNDS EP 1460077 9/2004 WO 02085904 10/2002 (75) Inventors: Patrick Robert Verhoest, Old Lyme, CT WO 2004037176 5/2004 (US); Caroline ProulX-Lafrance, Ledyard, CT (US) OTHER PUBLICATIONS Wunder et a1, M01. PharmacoL, v01. 28, N0. 6, (2005), pp. 1776 (73) Assignee: P?zer Inc., New York, NY (U S) 1781. van der Staay et a1, Neuropharmacology, v01. 55 (2008), pp. 908 ( * ) Notice: Subject to any disclaimer, the term of this 918. patent is extended or adjusted under 35 USC 154(b) by 562 days. Primary Examiner * Susanna Moore (74) Attorney, Agent, or Firm * Jennifer A. Kispert; (21) Appl.No.: 12/118,062 Michael Herman (22) Filed: May 9, 2008 (57) ABSTRACT (65) Prior Publication Data The invention provides PDE9-inhibiting compounds of For US 2009/0030003 A1 Jan. 29, 2009 mula (I), Related US. Application Data (60) Provisional application No. 60/917,333, ?led on May 11, 2007. (51) Int. Cl. C07D 48 7/04 (2006.01) A61K 31/519 (2006.01) A61P 25/28 (2006.01) (52) US. Cl. ................................... .. 514/262.1; 544/262 (58) Field of Classi?cation Search ................ .. 544/262; 5 1 4/2 62 .1 See application ?le for complete search history. and pharmaceutically acceptable salts thereof, Wherein R, R1, (56) References Cited R2 and R3 are as de?ned herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in U.S.
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives As Potent Cholinesterase Inhibitors
    biomolecules Article Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors 1,2, 1,2,3, 1,2 1,2 Barbora Svobodova y, Eva Mezeiova y, Vendula Hepnarova , Martina Hrabinova , Lubica Muckova 1,2 , Tereza Kobrlova 1 , Daniel Jun 1,2 , Ondrej Soukup 1,2, María Luisa Jimeno 4, José Marco-Contelles 3,* and Jan Korabecny 1,2,* 1 Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic 2 Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic 3 Laboratory of Medicinal Chemistry, Institute of General Organic Chemistry, Juan de la Cierva 3, 28006-Madrid, Spain 4 Centro de Química Orgánica “Lora-Tamayo” (CSIC), C/Juan de la Cierva 3, 28006-Madrid, Spain * Correspondence: [email protected] (J.M.-C.); [email protected] (J.K.); Tel.: +34-91-2587554 (J.M.-C.); +420-495-833-447 (J.K.) These authors contributed equally to this paper. y Received: 2 August 2019; Accepted: 17 August 2019; Published: 19 August 2019 Abstract: Tacrine was the first drug to be approved for Alzheimer’s disease (AD) treatment, acting as a cholinesterase inhibitor. The neuropathological hallmarks of AD are amyloid-rich senile plaques, neurofibrillary tangles, and neuronal degeneration. The portfolio of currently approved drugs for AD includes acetylcholinesterase inhibitors (AChEIs) and N-methyl-d-aspartate (NMDA) receptor antagonist. Squaric acid is a versatile structural scaffold capable to be easily transformed into amide-bearing compounds that feature both hydrogen bond donor and acceptor groups with the possibility to create multiple interactions with complementary sites.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Discovery and Development of Veterinary Pharmaceuticals in Telemetered Animals
    DISCOVERY AND DEVELOPMENT OF VETERINARY PHARMACEUTICALS IN TELEMETERED ANIMALS R. J. G. Zwijnenberg 2010 ISBN: 978‐90‐39354742 DISCOVERY AND DEVELOPMENT OF VETERINARY PHARMACEUTICALS IN TELEMETERED ANIMALS Ontdekking en ontwikkeling van veterinaire farmaceutische produkten in van telemeters voorziene dieren (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. J.C. Stoof, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op dinsdag 14 december 2010 des middags te 2.30 uur door: Raphaёl Johannes Gerhardus Zwijnenberg geboren op 22 december 1961 te Winterswijk Promotor: Prof. dr. J. Kirpensteijn Colophon My parents own a house in Palma de Gandia, Valencia, Spain. It is a typically Spanish house with many terraces and retaining walls. All these retaining walls have been built by hand by my parents. As they were building the retaining walls in their garden, my parents lovingly named each one of these walls by a different name. E.g. the longest wall was called “la Langedocienne” after a piece of the French autoroute that is long and doesn’t seem to end. The one wall I tried to help construct my parents named the “klaagmuur” in Dutch. The translation in English means “the wall of complaints” as the Wailing Wall is called in Dutch. I must have complained a lot during construction, or at least my parents thought so. Also doing a PhD by publication, as is the custom in the Netherlands, is a long process of writing and re‐ writing articles, sign‐off procedures, satisfying both scientific and company standards and procedures.
    [Show full text]
  • Stacey Jill Sukoff Rizzo Home Addres
    University of Pittsburgh School of Medicine CURRICULUM VITAE 2020 BIOGRAPHICAL Name: Stacey Jill Sukoff Rizzo Home Address: 2574 Corteland Drive Business Address: 100 Technology Drive Pittsburgh, PA 15241 556 Bridgeside Point I Home Phone: 1-860-772-7522 Pittsburgh, PA 15219 Email: [email protected] Business Phone: 1-412-383-3719 EDUCATION and TRAINING UNDERGRADUATE 1991-1995 Rutgers University, B.S. 1995 Animal Sciences New Brunswick, NJ, USA GRADUATE 2008-2012 University College Ph.D. 2012 Neuroscience London, United Kingdom Advisor: Stephen J. Moss, Ph.D. APPOINTMENTS and POSITIONS ACADEMIC 2019- Present Department of Neurobiology Associate Professor Department of Medicine – Aging Institute University of Pittsburgh Pittsburgh, PA USA Preclinical Phenotyping Core Director University of Pittsburgh Pittsburgh, PA USA NON-ACADEMIC 2014-2019 The Jackson Laboratory Associate Director, Center Bar Harbor, Maine, USA for Biometric Analysis Director, Mouse Neurobehavioral Phenotyping Facility 1 2011-2014 Pfizer Neuroscience Research Principle Research Scientist Cambridge, MA, USA 2010-2011 Pfizer Neuroscience Research Senior Research Scientist Groton, MA, USA 2003-2010 Wyeth Discovery Neuroscience Research Senior Research Scientist Princeton, NJ, USA 2001-2003 Aventis Pharmaceuticals Scientist Bridgewater, NJ, USA 1999-2001 Merck Research Laboratories Staff Biologist San Diego, CA, USA 1996-1999 Wyeth-Ayerst Research Scientist Princeton, NJ, USA 1995-1996 The Wistar Institute Research Technician Philadelphia, PA, USA MEMBERSHIP in PROFESSIONAL and SCIENTIFIC SOCIETIES Society for Neuroscience (SFN) 1996-present New York Academy of Sciences 2007-2010 International Behavioural and Neural Genetics Society (IBANGS) 2014-2016 International Behavioral Neuroscience Society (IBNS) 2015-present HONORS Aventis Achievement Award 2002 Wyeth peer nominated achievement awards 2004,2005,2007 Wyeth Discovery Research Annual Meeting Oral Presentation Award 2005 Wyeth “Research Scientist of the Year” Award 2006 PUBLICATIONS PEER REVIEWED REFEREED ARTICLES 1.
    [Show full text]
  • MAGID ABOU-GHARBIA, Phd
    MAGID ABOU-GHARBIA, PhD BUSINESS: Wyeth Research CN-8000 Princeton, NJ 08543-8000 Tel.: (732) 274-4522 Fax: (732) 274-4500 e-mail: [email protected] SUMMARY OF QUALIFICATIONS & ACCOMPLISHMENTS: Senior Vice President & Head of Chemical & Screening Sciences, responsible for overseeing and directing Wyeth Discovery chemistry and screening research efforts of 500 scientists at four Discovery sites in support of Neuroscience, Women’s Health/Bone, Inflammation, Oncology, Cardiovascular/Metabolic Diseases therapeutic areas. Twenty-five years of pharmaceutical research experience in Drug Discovery and Development resulting in the identification and development of multi New Chemical Entities (NCEs) and clinical candidates highlighted by: • The discovery of four Marketed Drugs and several drugs under clinical development including the first-in-class antidepressant, Effexor®, short-action hypnotic Sonata®, anti-cancer agent Mylotarg®, a broad-spectrum antibiotic Tygacil®, a non-steroidal HRT, Bazedoxifene®, an SNRI, Pristiq® (DVS-233) for vasomotor symptoms and depression and an anticancer cell cycle inhibitor, Torisel® (Temsirolimus, CCI-799). • Building a strong multi-disciplinary Chemical & Screening Sciences organization based on modern drug discovery technologies. • Establishing key enabling technologies such as HTS, Combinatorial Chemistry, SWAT (Synthetic Work-up Attack Team), Bioorganic/Enzymology, Chiral Technology, Pharmaceutical Profiling, Interface groups and two state-of-the-art compound lectrivers equipped with computerized inventory systems. • Fostering a highly creative environment focusing on innovation, productivity and contributing 9-12 drug candidates to the Wyeth pipeline on an annual basis. • Adding value to Wyeth marketed products (latest efforts were in support of the Premarin® and Effexor® franchises). • Contributions resulted in over 175 publications, presentations, invited lectures, inventor of 99 issued US patents and over 300 patents worldwide.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • American Journal of Veterinary Research
    American Journal of Veterinary Research Index for Volume 70 No. 1 – 12 January – December 2009 Published by AMERICAN VETERINARY MEDICAL ASSOCIATION 1931 N MEACHAM RD, SUITE 100, SCHAUMBURG, IL 60173-4360 Index to News A American College of Veterinary Ophthalmologists (ACVO) Abbott Animal Health ACVO awards Vision grants, 166 Abbott online CE begins with fl uid therapy, 1313 American College of Veterinary Pathologists (ACVP) Academy for Educational Development Industry sponsors renew support for pathology training positions, 439 US makes big push to prevent next global pandemic, 1440 American College of Veterinary Practitioners (ACVP) Accreditation ACVP announces diplomates, 317 Education council schedules site visits, 9 Council on Education updates schools’ statuses, 165 American College of Veterinary Sports Medicine and Rehabilitation Council schedules site visits, 438 (ACVSMR) Accreditation statuses reviewed by Council on Education, 689 Comments invited on proposed sports medicine and rehabilitation Six veterinary technology programs become accredited, 808 specialty, 318 AVMA board acts to improve Web site, veterinary internships; approves specialty, 940 American Kennel Club (AKC) AVMA invites award nominations, 1312 Addis Ababa University College of Veterinary Medicine Golden anniversary for Purdue veterinary school, 1181 American Recovery and Reinvestment Act USDA funding research, laboratory facility care, 1180 Adoption Feline health studies funded, 809 American Thoracic Society LSU research could affect care for humans and animals,
    [Show full text]
  • Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
    Florencio Zaragoza Dorwald¨ Lead Optimization for Medicinal Chemists Related Titles Smith, D. A., Allerton, C., Kalgutkar, A. S., Curry, S. H., Whelpton, R. van de Waterbeemd, H., Walker, D. K. Drug Disposition and Pharmacokinetics and Metabolism Pharmacokinetics in Drug Design From Principles to Applications 2012 2011 ISBN: 978-3-527-32954-0 ISBN: 978-0-470-68446-7 Gad, S. C. (ed.) Rankovic, Z., Morphy, R. Development of Therapeutic Lead Generation Approaches Agents Handbook in Drug Discovery 2012 2010 ISBN: 978-0-471-21385-7 ISBN: 978-0-470-25761-6 Tsaioun, K., Kates, S. A. (eds.) Han, C., Davis, C. B., Wang, B. (eds.) ADMET for Medicinal Chemists Evaluation of Drug Candidates A Practical Guide for Preclinical Development 2011 Pharmacokinetics, Metabolism, ISBN: 978-0-470-48407-4 Pharmaceutics, and Toxicology 2010 ISBN: 978-0-470-04491-9 Sotriffer, C. (ed.) Virtual Screening Principles, Challenges, and Practical Faller, B., Urban, L. (eds.) Guidelines Hit and Lead Profiling 2011 Identification and Optimization ISBN: 978-3-527-32636-5 of Drug-like Molecules 2009 ISBN: 978-3-527-32331-9 Florencio Zaragoza Dorwald¨ Lead Optimization for Medicinal Chemists Pharmacokinetic Properties of Functional Groups and Organic Compounds The Author All books published by Wiley-VCH are carefully produced. Nevertheless, authors, Dr. Florencio Zaragoza D¨orwald editors, and publisher do not warrant the Lonza AG information contained in these books, Rottenstrasse 6 including this book, to be free of errors. 3930 Visp Readers are advised to keep in mind that Switzerland statements, data, illustrations, procedural details or other items may inadvertently be Cover illustration: inaccurate.
    [Show full text]